Selection bias can be strong. In a survey comparing psychedelic enthusiasts to a more general sample, enthusiasts reported markedly larger quality-of-life gains, with a between-group difference around d = 0.84. Importantly, this gap remained even after adjusting for mindset, setting, motivation, and personality, and group membership was the strongest predictor of reported impact. These findings […]
Blog
Do therapeutic context and support buffer stress in difficult psychedelic trips?
Short answer: partly yes. In a large survey, a therapeutic-like setting and supportive relationships were linked to weaker connections between life stress, difficult psychedelic experiences, and some negative psychological outcomes. The buffering was not universal across all outcomes. In an international online survey of 1,867 psychedelic users reported in a recent study, researchers tested whether […]
Is psychedelic therapy no better than open-label antidepressants in depression?
Short answer: not proven. A recent comparison by researchers reported no greater effectiveness for psychedelic therapy than open-label antidepressants, but it relies on indirect comparisons across separate studies and is not a head-to-head trial: see the summary here. I cannot independently verify the conclusions beyond what the authors present. Psychedelic therapy is a package of […]
What predicts psychedelic therapy success in depression, especially in-session?
In-session factors appear to be the strongest predictors of antidepressant improvement in psychedelic-assisted therapy. Emotional breakthrough, mystical or unitive qualities, and ego dissolution paired with insight or reappraisal were most often linked with larger and more durable symptom reductions. Anxiety-dominant or dysphoric states tended to coincide with smaller gains, even when overall intensity was high. […]
Are psilocybin truffles bad for your health?
Psilocybin truffles are not inherently bad for your health, but they are not risk free. Effects vary with dose, mindset, and environment, and long term outcomes are not well established. Risks can include acute anxiety or panic, nausea, confusion, and short term increases in heart rate and blood pressure. Use is generally discouraged for people […]
What sets Gijs Tecklenburg apart as a therapist and tripsitter?
Gijs Tecklenburg stands out for a calm, attentive, and deeply present way of working. He favors space over control and attunement over technique, helping clients find insight without forcing the process. His background combines many years in Dutch mental health care with extensive mindfulness work. He integrates approaches like mindfulness, ACT, breathwork, neurofeedback, and especially […]
Is psychedelic therapy right for childhood trauma and loneliness on Vyvanse?
Psychedelic therapy can help some people explore childhood-rooted loneliness and fear by bringing buried feelings to the surface in a supported setting. It is not a quick fix and it is not right for everyone. Careful screening, a legal context, and an experienced facilitator are essential. Because you use Vyvanse, extra caution is needed. Stimulants […]
What do clients say about Triptherapie therapists and tripsitters?
Client reviews on the Triptherapie forum consistently mention feeling safe, seen, and well supported during guided sessions. You can browse a broader sample of experiences in this review overview. These are client reports and I cannot verify individual outcomes. Marcel is often described as calm, professional, and empathic, creating trust for both individuals and couples […]
Is it safe to mix ADHD meds with psilocybin, MDMA, LSD, ketamine, or ayahuasca?
Short answer: mixing prescription ADHD stimulants (like lisdexamfetamine, methylphenidate, or dexamfetamine) with psychedelics can raise the chance of overstimulation, anxiety, and cardiovascular strain. Risk varies by substance and setting. Highest concern is ayahuasca, because it contains MAO‑A inhibitors. Stimulants combined with MAOIs are widely warned against in official product information (see the Dutch SmPC for […]
Does MDA produce stronger, longer-lasting and more adverse effects than MDMA?
Yes. A recent double-blind, randomized, placebo-controlled crossover study in 23 healthy participants directly compared equimolar doses of MDMA and MDA and found that MDA produced stronger and longer-lasting acute effects than MDMA, with more adverse and psychedelic-like effects (study). On average, the subjective drug effect lasted about 6.1 hours with MDA versus 4.1 hours with […]
Does a single MM120 treatment reduce GAD symptoms, and which dose works best?
Yes. In a phase 2b randomized trial, a single dose of MM120 reduced generalized anxiety disorder symptoms at 4 weeks versus placebo, showing a dose response. The 100 µg and 200 µg doses produced statistically significant improvements on the Hamilton Anxiety Rating Scale compared with placebo, by about 5 and 6 points respectively. The 25 […]
Does psilocybin reduce brain blood flow and narrow arteries via 5-HT2A?
Short answer: Yes, in healthy volunteers psilocybin was associated with a temporary reduction in cerebral blood flow and a narrowing of the internal carotid artery. The pattern is consistent with involvement of 5-HT2A receptors, since psilocybin is an agonist and the 5-HT2A antagonist ketanserin did not show similar effects, but this is not definitive proof […]